[go: up one dir, main page]

EA201300867A1 - ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ - Google Patents

ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ

Info

Publication number
EA201300867A1
EA201300867A1 EA201300867A EA201300867A EA201300867A1 EA 201300867 A1 EA201300867 A1 EA 201300867A1 EA 201300867 A EA201300867 A EA 201300867A EA 201300867 A EA201300867 A EA 201300867A EA 201300867 A1 EA201300867 A1 EA 201300867A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase inhibitors
mtor kinase
virus agents
modulators
mtor
Prior art date
Application number
EA201300867A
Other languages
English (en)
Inventor
Томас Е. Шенк
Джи-Ин Ким
Original Assignee
Дзе Трастиз Оф Принстон Юнивесити
Кадмон Корпорейшн Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Принстон Юнивесити, Кадмон Корпорейшн Ллк filed Critical Дзе Трастиз Оф Принстон Юнивесити
Publication of EA201300867A1 publication Critical patent/EA201300867A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к способам лечения или предотвращения вирусных инфекций с использованием модуляторов ферментов клетки-хозяина, имеющих отношение к mTOR. Это изобретение также относится к способам лечения и предотвращения вирусных инфекций с использованием модуляторов ферментов клетки-хозяина, имеющих отношение к mTOR, и модуляторов реакции несвернутых белков.
EA201300867A 2011-01-27 2012-01-27 ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ EA201300867A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436970P 2011-01-27 2011-01-27
PCT/US2012/023035 WO2012103524A2 (en) 2011-01-27 2012-01-27 Inhibitors of mtor kinasa as anti- viral agents

Publications (1)

Publication Number Publication Date
EA201300867A1 true EA201300867A1 (ru) 2014-03-31

Family

ID=46581443

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300867A EA201300867A1 (ru) 2011-01-27 2012-01-27 ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ

Country Status (6)

Country Link
US (1) US20140206678A1 (ru)
EP (1) EP2667874A4 (ru)
JP (1) JP2014505076A (ru)
CA (1) CA2825825A1 (ru)
EA (1) EA201300867A1 (ru)
WO (1) WO2012103524A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022185A2 (en) * 2012-08-03 2014-02-06 Albert Einstein College Of Medicine Of Yeshiva University Method to treat or prevent herpesvirus infections
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
CN112274641A (zh) 2014-01-28 2021-01-29 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
WO2016064683A1 (en) * 2014-10-24 2016-04-28 St. Jude Children's Research Hospital Coordinated metabolic reprogramming in response to productive viral infections
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US20240033236A1 (en) * 2020-10-13 2024-02-01 The Board Of Trustees Of The University Of Illinois Methods of treating herpes viral infection with 4-phenylbutyrate (pba) or a pharmaceutically acceptable salt thereof
WO2022106579A1 (en) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for treating a disease associated with macrophage senescence
CN114652728A (zh) * 2022-04-29 2022-06-24 广东龙帆生物科技有限公司 一种Apitolisib在制备用于抗腺病毒感染的药物中的用途
CN114652727B (zh) * 2022-04-29 2023-10-27 广东龙帆生物科技有限公司 一种wye-125132在制备用于抗腺病毒感染的药物中的用途
CN114767686A (zh) * 2022-04-29 2022-07-22 暨南大学 Pf-04691502在制备预防和/或治疗腺病毒感染的药物中的应用
CN114948971A (zh) * 2022-04-29 2022-08-30 广东龙帆生物科技有限公司 一种Vistusertib在制备用于抗腺病毒感染的药物中的用途
CN114748482B (zh) * 2022-04-29 2023-09-26 广东龙帆生物科技有限公司 一种pf-04691502在制备用于抗腺病毒感染的药物中的用途
CN115381828B (zh) * 2022-08-04 2023-04-28 武汉市金银潭医院(武汉市传染病医院) Pilaralisib在制备抗肠道病毒71型药物中的应用
WO2025210119A1 (en) * 2024-04-04 2025-10-09 Aarhus Universitet Pi3k and/or mtor inhibitors for treating viral disease
CN119055654B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Voxtalisib在制备抗ADV7病毒药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
DE60204452T2 (de) * 2001-04-27 2005-12-15 Smithkline Beecham Corp. Pyrazolo[1,5a]Pyridinderivate
EP2046799B1 (en) * 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
PT2024372E (pt) * 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
CA2650290C (en) * 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
WO2007146024A2 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
RU2470936C2 (ru) * 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
CN101616672A (zh) * 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
EP2572712A3 (en) * 2007-06-01 2013-11-20 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2009143313A1 (en) * 2008-05-23 2009-11-26 Wyeth Triazine compounds as p13 kinase and mtor inhibitors
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP2318002A4 (en) * 2008-08-05 2012-11-28 Univ Emory USE OF MTOR INHIBITORS FOR INCREASING IMMUNE RESPONSES OF T CELLS
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AU2010203512C1 (en) * 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CN101869568A (zh) * 2009-04-27 2010-10-27 中国医学科学院基础医学研究所 细胞自噬(ⅱ型细胞凋亡)作用抑制剂的用途
US20140018354A9 (en) * 2009-07-23 2014-01-16 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents
US9149445B2 (en) * 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
WO2011103516A2 (en) * 2010-02-18 2011-08-25 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals

Also Published As

Publication number Publication date
JP2014505076A (ja) 2014-02-27
WO2012103524A3 (en) 2012-09-20
EP2667874A2 (en) 2013-12-04
WO2012103524A8 (en) 2013-09-12
EP2667874A4 (en) 2014-07-30
WO2012103524A2 (en) 2012-08-02
US20140206678A1 (en) 2014-07-24
CA2825825A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
BR112013021134A2 (pt) moduladores e métodos de uso
BR112013005116A2 (pt) moduladores e métodos de uso
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
BR112013004776A2 (pt) moduladores de proteína notum e métodos de uso
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
BR112013014119A8 (pt) Novos moduladores e métodos de uso
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201490450A1 (ru) Новые ингибиторы ферментов
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201790309A1 (ru) Антитела к fap, способы их получения и применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения